Bharat Biotech readying Tuberculosis, Cholera vaccines
Suchitra Ella says BBIL has stopped production of the COVID-19 vaccines as done by other manufacturers worldwide
bharat biotech
July 2024
April 2023
January 2023
December 2022
November 2022
September 2022
June 2022
May 2022
Pharma’s R&D Ambitions Go Global
India’s life sciences R&D is undergoing a sea change. Given the huge risks and investments involved, can India taste success in innovative medicine, therapy and diagnostic tools?
India's first nasal Covid vaccine iNCOVACC launched; priced at ₹325/dose
Bharat Biotech’s vaccine dubbed as “game changer”; to offer efficient distribution and easy and pain-free administration.
COVAXIN successfully completes phase 2/3 trials in U.S.
The results show no adverse effects were seen in clinical trials; the company says the vaccine is an alternative for those hesitant to receive mRNA jabs in the U.S.
Bharat Biotech's Covid-19 nasal vaccine to cost ₹800 in pvt market, ₹325 for govt supplies
The iNCOVACC vaccine received Indian drug regulator's approval to be used as a booster dose for the adult population.
Bharat Biotech's intranasal Covid-19 vaccine to be available on Co-WIN app from today
The vaccine will be available on the Co-WIN platform for persons aged above 18 years for primary 2 dose schedule, homologous booster doses, from Friday evening.
Bharat Biotech’s intra-nasal vaccine approved as primary, heterologous booster
iNCOVACC becomes the world’s first intranasal vaccine to receive both primary series and heterologous booster approval.
Bharat Biotech's intranasal Covid-19 vaccine approved for restricted use
It’s India's first nasal vaccine against Covid-19. Health minister Mansukh Mandaviya says it’ll further strengthen country's fight against pandemic
COVAXIN shows safety, immunogenicity in children aged 2-18 years: Lancet
Peer-reviewed data has been published in Lancet Infectious Diseases; phase II-III study was held to evaluate safety, and immunogenicity of COVAXIN among healthy children and adolescents.
$19.3 million to Bharat Biotech consortium for ‘variant-proof’ Covid vaccine
The funding seeks to establish preclinical and clinical proof of concept for a vaccine designed to provide protection against all known SARS-CoV-2 variants.
